BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to o ...